In a global first, Uganda’s Ministry of Health, the World Health Organization (WHO) and other partners today launched a first-ever clinical efficacy trial for a vaccine from Ebola from the Sudan ...

The FDA has approved Avtozma® (tocilizumab-anoh), a biosimilar to Actemra®, in both intravenous and subcutaneous formulations.

The FDA's approval is grounded in an evidence totality and comprehensive data package, which includes outcomes from a study.

However, a notable challenge in the management of RA is the immunogenicity of these biologic therapies, which can lead to the formation of anti-drug antibodies (ADAb). These antibodies can reduce ...

The biosimilar will be available in both subcutaneous and intravenous formulations and has nearly all the same indications as ...

Immunogenicity was assessed by hemagglutination-inhibition (HI) prevaccination and 28 days after each vaccination. Immunogenic non-inferiority QIV versus TIV for shared strains, and superiority ...

Operator Good day, everyone and welcome to Pfizer's fourth-quarter 2024 earnings conference call. Today's call is being ...

Association between ctDNA levels, timing of blood collection, and overall survival in metastatic colorectal cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers ...

Introduction: TNFα inhibitor (TNFi) immunogenicity in rheumatoid arthritis (RA) is a major obstacle to its therapeutic effectiveness. Although methotrexate (MTX) can mitigate TNFi immunogenicity, its ...